News Home

Is it Time to Dump Citius Pharmaceuticals Inc (CTXR) Stock After it Has Fallen 2.46% in a Week?

Tuesday, August 30, 2022 03:42 PM | InvestorsObserver Analysts
Is it Time to Dump Citius Pharmaceuticals Inc (CTXR) Stock After it Has Fallen 2.46% in a Week?

Citius Pharmaceuticals Inc (CTXR) stock is down 2.46% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Citius Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTXR!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CTXR Stock Today?

Citius Pharmaceuticals Inc (CTXR) stock is trading at $1.19 as of 3:41 PM on Tuesday, Aug 30, a drop of -$0.06, or -4.8% from the previous closing price of $1.25. The stock has traded between $1.18 and $1.27 so far today. Volume today is low. So far 420,206 shares have traded compared to average volume of 718,419 shares.

More About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. Click Here to get the full Stock Report for Citius Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App